Krystal Biotech (KRYS) Operating Income (2016 - 2026)

Krystal Biotech has reported Operating Income for 11 years, with the latest figure at $58.4 million in Q2 2026.

• Operating Income for Q2 2026 came in at $58.4 million, up 48.27% year-over-year; the trailing twelve-month figure through Jun 2026 was $197.8 million (up 41.76% YoY), and the FY2025 annual result was $161.3 million, up 145.32% from the prior year.
• Operating Income rose to $58.4 million in Q2 2026, from $53.7 million in the prior quarter.
• Over five years, Operating Income peaked at $58.4 million in Q2 2026 and troughed at -$50.2 million in Q1 2022.
• A 5-year average of $4.7 million and a median of $5.9 million in 2023 frame the typical range for Operating Income.
• The widest annual swing landed in 2022, when Operating Income plunged 249.91%; it then surged 1173.86% in 2024.
• A 5-year view of Operating Income shows it stood at -$34.8 million in 2022, then soared by 109.34% to $3.2 million in 2023, then surged by 1173.86% to $41.4 million in 2024, then gained by 7.0% to $44.3 million in 2025, then jumped by 31.96% to $58.4 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were $58.4 million in Q2 2026, $53.7 million in Q1 2026, and $44.3 million in Q4 2025.